A comparative study of milnacipran and imipramine in the treatment of major depressive disorder
A comparative study of milnacipran and imipramine in the treatment of major depressive disorder
复制标题
米那普仑与丙咪嗪治疗重度抑郁症的对照研究
DOI：
10.1185/030079904125003719
复制
发表时间：
2004
影响因子：
2.3
通讯作者：
the Spanish Milnacipran/Imipramine Study Group
中科院分区：
文献类型：
--
作者：
J. López;A. Conesa;the Spanish Milnacipran/Imipramine Study Group
在西班牙5家医院中心进行的一项多中心、双盲、随机、平行组比较试验中，对milnacipran（一种抑制血清素和去甲肾上腺素再摄取的双作用抗抑郁药）与三环抗抑郁药丙咪嗪的抗抑郁疗效和安全性进行了比较。根据美国精神病学协会诊断与统计手册（第三版）诊断为重度抑郁症的100名住院患者，在蒙哥马利和Åsberg抑郁评定量表上最低得分为25分，用milnacpran（100毫克/天）或丙咪嗪（150毫克/天）治疗6周。两种治疗方法在减轻抑郁症状方面表现出相似的疗效。milnacpran治疗组大多数不良事件的发生率低于丙咪嗪组，特别是与抗胆碱能症状相关的不良事件。然而，milnacpran更常见的症状是排尿困难和颤抖。这项研究的结果支持了其他已经证明milnacpran与三环抗抑郁药（如丙咪嗪）具有同等疗效但耐受性更好的研究。
SUMMARY The antidepressant efficacy and safety of milnacipran, a dual action antidepressant drug which inhibits the reuptake of serotonin and noradrenaline, was compared with that of the tricyclic antidepressant, imipramine, in a multi-centre, double-blind, randomised, parallel group, comparative trial in 5 hospital centres in Spain. One hundred patients hospitalised with a diagnosis of major depressive disorder according to the Diagnostic and Statistical Manual of the American Psychiatry Association (third revision), with a minimum score of 25 on the Montgomery and Åsberg Depression Rating Scale were treated for 6 weeks with milnacipran (100 mg/day) or imipramine (150 mg/day). Both treatments showed similar efficacy in reducing depressive symptoms. The frequency of most adverse events in the milnacipran-treated patients was lower than that observed in the imipramine group, particularly those related to anticholinergic symptoms. Dysuria and shivering, however, were more common with milnacipran. The results of this study support others which have demonstrated that milnacipran has equivalent efficacy but superior tolerability to a tricyclic antidepressant such as imipramine.